USD0.000æéå€ååŒÂ  (ET)
1.70BæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
Maravai LifeSciences Holdings Inc
äž»èŠããŒã¿
6.760å§å€
6.770é«å€
1.09Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
0.75%売買å転ç
6.750忥çµå€
6.450å®å€
5.06M売買代é
æå€±é¡æ ªäŸ¡åçç
4.50PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-22.03%ç·è³ç£å©çç
4.99552é±é«å€
0.61åºæ¥é«æ¯ç%
-144.85MçŽå©ç
145.32Mæ ªåŒæ°
-0.72261æ ªåœããå©çïŒEPSïŒ
0.69ããŒã¿å€
-40.83%èªå·±è³æ¬å©çç
1.99052é±å®å€
4.74%æ¯ãå¹
51.19%ç²å©çç
1.70BæäŸ¡ç·é¡
3.84ãªã¹ã¯ãªã¿ãŒã³
3.75%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Maravai LifeSciences Holdings Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž31äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯5.90ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯è¯å¥œã§ããã¡ã³ãã¡ã³ã¿ã«ãºãåªããŠããŸãããããã¯ãã«ã«ã¯çŸåšã®ãã¬ã³ããè£ä»ãããã®ã§ã¯ãããŸãããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Maravai LifeSciences Holdings Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Maravai LifeSciences Holdings Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Maravai LifeSciences Holdings Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Maravai LifeSciences Holdings Inc
MRVI
9
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
ææšî
ææš
売ã(4)
äžç«(2)
è²·ã(0)
ç§»åå¹³å
売ã(3)
äžç«(0)
è²·ã(3)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Maravai LifeSciences Holdings Incã®äŒæ¥æ
å ±î
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customersâ research, therapeutic and vaccine programs. This segmentâs business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segmentâs business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
äŒæ¥ã³ãŒãMRVI
äŒæ¥åMaravai LifeSciences Holdings Inc
æé«çµå¶è²¬ä»»è
ãCEOãBrust (Bernd)
ãŠã§ããµã€ãhttps://www.maravai.com/
æ ªäž»çµ±èšî
ãããã質å
Maravai LifeSciences Holdings IncïŒMRVIïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îMaravai LifeSciences Holdings IncïŒMRVIïŒã®çŸåšã®æ ªäŸ¡ã¯6.57ã§ãã
Maravai LifeSciences Holdings Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îMaravai LifeSciences Holdings Incã®ãã£ãã«ãŒã·ã³ãã«ã¯MRVIã§ãã
Maravai LifeSciences Holdings Incã®52é±é«å€ã¯ãããã§ããïŒ
îMaravai LifeSciences Holdings Incã®52é±é«å€ã¯5.00ã§ãã
Maravai LifeSciences Holdings Incã®52é±å®å€ã¯ãããã§ããïŒ
îMaravai LifeSciences Holdings Incã®52é±å®å€ã¯1.99ã§ãã
Maravai LifeSciences Holdings Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îMaravai LifeSciences Holdings Incã®æäŸ¡ç·é¡ã¯1.70Bã§ãã
Maravai LifeSciences Holdings Inc (MRVI) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãMaravai LifeSciences Holdings IncïŒMRVIïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯5.90ã§ãã
Maravai LifeSciences Holdings Inc (MRVI) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îMaravai LifeSciences Holdings IncïŒMRVIïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.91ã§ãã